
23 Feb Avery Therapeutics
Jordan Lancaster, Ph.D., CEO
Oct. 8 | 1:30pm | FLW Ballroom G
Tucson, AZ
(Private)
Avery Therapeutics is a late-stage pre-clinical company developing a new class of restorative medicine for patients with intractable diseases of inflammation and fibrosis by levering the therapeutic potential within the immune system. Avery’s lead clinical candidate AT-102 uses our proprietary MPhase biologic platform to address heart failure, one of the leading causes of death in the world. In pre-clinical models, AT-102 structures the heart to improve and establishes best-in-class efficacy.